MetaCap

CG Oncology (CGON) vs Krystal Biotech (KRYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CG Oncology (CGON) has outperformed Krystal Biotech (KRYS) over the past year, gaining 87.3% versus a gain of 45.7%. Krystal Biotech is the larger company by market cap ($9.15 billion vs $7.10 billion), about 1.3 times the size, while CG Oncology is growing revenue faster (+254.7% vs +33.9%). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus -3985.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGON+87.25%KRYS+45.69%
+105%+44%-18%
Nov 21, 20251 yearNov 20, 2026
CGON+126.86%KRYS+166.22%
+237%+86%-65%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGON versus KRYS key metrics
MetricCGONKRYS
Share price$79.47$308.89
Market cap$7.10B$9.15B
1-day change-2.97%-2.19%
YTD return+91.40%+25.29%
1-year return+87.25%+45.69%
5-year return—+675.91%
P/E ratio (TTM)—41.97
Forward P/E—33.47
EPS (TTM)$-2.76$7.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.04M$389.13M
Revenue growth (YoY)+254.70%+33.94%
Net income (latest FY)$-161.00M$204.83M
Operating margin-4722.13%41.45%
Net margin-3985.02%52.64%
52-week high$93.95$382.54
52-week low$37.01$212.02
Distance from 52-week high-15.41%-19.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+38.03%+25.68%
Average volume1.24M283.88K
Shares outstanding89.32M29.63M
Employees142295
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGON has outperformed KRYS by 41.6 percentage points over the past year.
  • Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
  • CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +33.94%).

About CG Oncology

CGON stock →

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

About Krystal Biotech

KRYS stock →

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees

CGON vs KRYS FAQ

Which is bigger, CG Oncology or Krystal Biotech?

Krystal Biotech (KRYS) is larger, with a market capitalization of $9.15B compared with $7.10B for CG Oncology (CGON).

Which stock has performed better over the past year, CGON or KRYS?

CGON returned +87.25% over the past 12 months, compared with +45.69% for KRYS (price return, excluding dividends). Past performance does not predict future results.

Are CG Oncology and Krystal Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons